<?xml version="1.0" encoding="UTF-8"?>
<p>The Buckner group at the University of Washington found that compounds bearing 
 <italic>N</italic>-containing heteroaromatic bicyclic rings inhibit methionyl-tRNA synthetase (MetRS) for antibacterial treatment [
 <xref rid="B54-biomolecules-10-01625" ref-type="bibr">54</xref>,
 <xref rid="B55-biomolecules-10-01625" ref-type="bibr">55</xref>]. A total of 249 compounds with four major different scaffolds were synthesized and tested in 13 different in vitro assays against MetRS (
 <italic>Trypanosoma brucei</italic>) ATP depletion (A), MetRS (
 <italic>S. aureus</italic>) ATP depletion (B), MetRS (
 <italic>Brudella</italic>) ATP depletion (C), MetRS (
 <italic>Giardia</italic>) aminoacylation (D), 
 <italic>T. brucei</italic> (E), 
 <italic>Trypanosoma cruzi</italic> (F)
 <italic>, Giardia intestinalis</italic> (ATCC50508) (G), 
 <italic>Leishmania</italic>
 <italic>amazonensis</italic> (H)
 <italic>, P. falciparum</italic> (3D7) (I), 
 <italic>S. aureus</italic> (ATCC29213) (J), 
 <italic>S. aureus</italic> MRSA (ATCC43300) (K), 
 <italic>Enterococcus faecalis</italic> (ATCC29212) (L), and 
 <italic>Enterococcus faecium</italic> (ATCC51559) (M). Two compounds bearing the same scaffold of pyridoimidazole, 
 <bold>45</bold> and 
 <bold>46</bold>, showed excellent potency in bacterial MetRS inhibition (IC
 <sub>50</sub>), bacterial growth inhibition (EC
 <sub>50</sub>), and MIC values in most of the in vitro cell assays (
 <xref ref-type="fig" rid="biomolecules-10-01625-f016">Figure 16</xref>).
</p>
